On July 30, Jianda Kyushu Biotechnology Co., Ltd. announced the completion of Series A financing of hundreds of millions of yuan. This round of financing was led by Taiping Healthcare Fund and added by a fund owned by Huatai Zijin, an old shareholder. Many institutions such as Gao Rong Venture Capital, Dachen CITIC Capital, and Botuo Biotech Brain Machine Fund followed the investment, and old shareholders such as the Beijing Medical and Health Industry Investment Fund and Kaifeng Venture Capital continued to raise their investment. Xiqiao Capital acted as financial advisor for this round of financing. According to Kinda Kyushu, this round of financing will focus on promoting clinical verification of the company's core pipelines, speeding up back-up pipeline development and the double reporting process between China and the US, further strengthening the company's platform capabilities in cutting-edge brain science and technology fields such as chemical genetics and optogenetics, and continuing to produce innovative global drugs using precise neuromodulation to treat intractable brain diseases.

Zhitongcaijing · 1d ago
On July 30, Jianda Kyushu Biotechnology Co., Ltd. announced the completion of Series A financing of hundreds of millions of yuan. This round of financing was led by Taiping Healthcare Fund and added by a fund owned by Huatai Zijin, an old shareholder. Many institutions such as Gao Rong Venture Capital, Dachen CITIC Capital, and Botuo Biotech Brain Machine Fund followed the investment, and old shareholders such as the Beijing Medical and Health Industry Investment Fund and Kaifeng Venture Capital continued to raise their investment. Xiqiao Capital acted as financial advisor for this round of financing. According to Kinda Kyushu, this round of financing will focus on promoting clinical verification of the company's core pipelines, speeding up back-up pipeline development and the double reporting process between China and the US, further strengthening the company's platform capabilities in cutting-edge brain science and technology fields such as chemical genetics and optogenetics, and continuing to produce innovative global drugs using precise neuromodulation to treat intractable brain diseases.